Mucking around with figures

While statins certainly are lifesaving for those with high cholesterol or established heart disease, their benefits are more modest for those at fairly low risk of heart disease: About 0.72 percent of the statin takers in the trial had a heart attack or stroke compared with 1.5 percent of those taking placebos.

Source: http://health.usnews.com/health-news/family-health/heart/articles/2008/11/11/6-ways-to-reduce-inflammation--without-a-statin-or-a-heart-test

The recent JUPITER trial demonstrated that potent statin therapy can cut by half the risk of future heart attack and stroke among men and women with low levels of LDL-cholesterol who are at increased vascular risk due to elevated levels of CRP, a biomarker of inflammation.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817490/

For example, in JUPITER, almost all of the cases of “incident diabetes” were in those with impaired fasting glucose at baseline, and this group had nearly a 50% reduction in rates of myocardial infarction, stroke, and cardiovascular death. 

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836530/

Dr Steven Nissen (Cleveland Clinic, OH) told heartwire that such large reductions in clinical events in less than two years among patients considered healthy by conventional definitions is likely to change the guidelines.

"Ideally, if a patient comes to me with normal LDL-cholesterol levels--in JUPITER, the median LDL-cholesterol level was 108 mg/dL--I tell him to keep doing what he's doing and to go about his business," said Nissen. "Now, what happens when that same patient arrives in my office and I know his CRP is elevated? I know that treating him with intensive statin therapy, despite what the guidelines state, is going to cut his risk of cardiovascular morbidity and mortality in half."

Source: http://www.medscape.com/viewarticle/583269

The recent JUPITER trial demonstrated that potent statin therapy reduces by 50 percent the risk of heart attack and stroke among men and women with low levels of LDL-cholesterol who are at increased vascular risk due to elevated levels of CRP, a biomarker of low-grade systemic inflammation. In JUPITER, both absolute risk and the absolute risk reduction with statin therapy in JUPITER were related to the level of CRP whereas no such relationship was observed for LDL-C.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817490/

The trial analyzed 17,802 patients without evidence of heart disease but with high CRP levels. In 2008, results presented at the American Heart Association meeting and published in the New England Journal of Medicine found that patients with low-to-normal LDL cholesterol receiving rosuvastatin had a lower rate of major cardiovascular events. Compared to patients taking a placebo, patients given rosuvastatin had reductions in LDL and CRP levels, and a reduction of 0.2% to 0.6% in their absolute risk of heart attack, stroke, and death at 1 year.^[4][5][6] The study's authors estimated that the number needed to treat with rosuvastatin to prevent one cardiovascular event was 95 over 2 years, extrapolated to 25 over 5 years

https://en.wikipedia.org/wiki/JUPITER_trial